| Symbol | CLDX |
|---|---|
| Name | CELLDEX THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Address | 53 FRONTAGE ROAD,SUITE 220, PERRYVILLE III BUILDING, HAMPTON, New Jersey, 08827, United States |
| Telephone | +1 908 200-7500 |
| Fax | — |
| — | |
| Website | https://www.celldex.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. Additional info from NASDAQ: |
2026-04-29 18:36
New Form SCHEDULE 13G - Celldex Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0002100119-26-000279 <b>Size:</b> 7 KB
Read more
2026-04-29 09:02
New Form ARS - Celldex Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001104659-26-050885 <b>Size:</b> 2 MB
Read more
2026-04-06 14:53
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read more
2026-04-02 18:15
New Form 424B5 - Celldex Therapeutics, Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001104659-26-039255 <b>Size:</b> 592 KB
Read more
2026-04-02 12:08
(99% Neutral) CELLDEX THERAPEUTICS, INC. (CLDX) Announces Clinical Development Update
Read more
2026-04-02 01:48
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
Read more
2026-04-01 17:08
New Form 424B5 - Celldex Therapeutics, Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001104659-26-038501 <b>Size:</b> 436 KB
Read more
2026-03-27 14:30
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03067935 | Individual Patient Expanded Access-Glembatumumab Vedotin | — | Metastatic gpNMB Expressing Triple Negative Breast Cancer | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut | — | Recurrent GBM | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07330778 | A Study of CDX-622 in Participants With Mild to Moderate Asthma | Phase1 | Mild to Moderate Asthma | Recruiting | 2026-02-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT07266402 | A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versu… | Phase3 | Chronic Inducible Urticaria | Recruiting | 2026-01-15 | 2028-10-01 | ClinicalTrials.gov |
| NCT07256392 | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Partici… | Phase3 | Chronic Spontaneous Urticaria | Recruiting | 2025-11-25 | 2028-09-01 | ClinicalTrials.gov |
| NCT06727552 | A Study of Barzolvolimab in Patients With Atopic Dermatitis | Phase2 | Atopic Dermatitis | Active_Not_Recruiting | 2024-12-18 | 2027-05-01 | ClinicalTrials.gov |
| NCT06650761 | A Phase I Study of CDX-622 | Phase1 | Healthy Participants | Completed | 2024-11-01 | 2026-04-24 | ClinicalTrials.gov |
| NCT06455202 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtic… | Phase3 | Chronic Spontaneous Urticaria | Active_Not_Recruiting | 2024-07-19 | 2027-04-01 | ClinicalTrials.gov |
| NCT06445023 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtic… | Phase3 | Chronic Spontaneous Urticaria | Active_Not_Recruiting | 2024-07-11 | 2027-04-01 | ClinicalTrials.gov |
| NCT06366750 | A Study of Barzolvolimab in Patients With Prurigo Nodularis | Phase2 | Prurigo Nodularis | Active_Not_Recruiting | 2024-04-12 | 2027-03-01 | ClinicalTrials.gov |
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1… | Phase2 | Ovarian Clear Cell Adenocarcinoma | Recruiting | 2024-03-12 | 2026-12-30 | ClinicalTrials.gov |
| NCT05774184 | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | Phase2 | Eosinophilic Esophagitis | Completed | 2023-06-01 | 2026-01-23 | ClinicalTrials.gov |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | Phase1 | Non-small Cell Lung Cancer | Completed | 2023-05-11 | 2025-05-21 | ClinicalTrials.gov |
| NCT05349890 | Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engine… | Phase1 | Malignant Epithelial Neoplasms | Active_Not_Recruiting | 2023-04-03 | 2028-04-15 | ClinicalTrials.gov |
| NCT05484011 | A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metas… | Phase1 | Metastatic Pancreatic Adenocarcinoma | Terminated | 2022-12-15 | 2024-03-04 | ClinicalTrials.gov |
| NCT05405660 | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | Phase2 | Chronic Inducible Urticaria | Completed | 2022-06-28 | 2025-09-12 | ClinicalTrials.gov |
| NCT05368285 | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Phase2 | Chronic Spontaneous Urticaria | Completed | 2022-05-19 | 2024-12-20 | ClinicalTrials.gov |
| NCT05029999 | CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | Phase1 | HER2-negative Breast Cancer | Recruiting | 2022-04-20 | 2026-04-20 | ClinicalTrials.gov |
| NCT04930783 | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | Phase1 | Melanoma | Active_Not_Recruiting | 2022-01-03 | 2030-09-30 | ClinicalTrials.gov |
| NCT04944862 | A Study of CDX-0159 in Patients With Prurigo Nodularis | Phase1 | Prurigo Nodularis | Completed | 2021-11-08 | 2023-07-31 | ClinicalTrials.gov |
| NCT05031624 | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects | Phase1 | Healthy Subjects | Completed | 2021-08-30 | 2022-01-14 | ClinicalTrials.gov |
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Pat… | Phase2 | Pancreatic Cancer | Terminated | 2021-08-13 | 2023-11-21 | ClinicalTrials.gov |
| NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy | Phase1 | Non Small Cell Lung Cancer | Terminated | 2021-01-01 | 2022-08-18 | ClinicalTrials.gov |
| NCT04548869 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX… | Phase1 | Cold Urticaria | Completed | 2020-11-24 | 2023-05-12 | ClinicalTrials.gov |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and … | Phase1 | Melanoma | Completed | 2020-09-28 | 2024-03-14 | ClinicalTrials.gov |
| NCT04538794 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Phase1 | Chronic Spontaneous Urticaria | Completed | 2020-09-24 | 2023-01-17 | ClinicalTrials.gov |
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without … | Phase2 | Glioblastoma | Active_Not_Recruiting | 2020-08-26 | 2026-03-01 | ClinicalTrials.gov |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced… | Phase1 | Non-small Cell Lung Cancer | Completed | 2020-08-04 | 2023-04-06 | ClinicalTrials.gov |
| NCT03804944 | Converting HR+ Breast Cancer Into an Individualized Vaccine | Phase2 | Breast Cancer | Recruiting | 2020-03-17 | 2027-12-31 | ClinicalTrials.gov |
| NCT04146129 | A Phase 1 Study of CDX-0159 | Phase1 | Healthy Subjects | Completed | 2019-10-29 | 2020-06-26 | ClinicalTrials.gov |
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | Phase1 | Non-Hodgkin's Lymphoma | Unknown | 2019-04-05 | 2025-03-01 | ClinicalTrials.gov |
| NCT03617328 | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stag… | Phase1 | Melanoma | Completed | 2018-11-13 | 2024-01-19 | ClinicalTrials.gov |
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination … | Phase1 | Melanoma | Terminated | 2018-07-06 | 2018-09-26 | ClinicalTrials.gov |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-a… | Early_Phase1 | Triple Negative Breast Cancer | Withdrawn | 2018-05-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab … | Phase1 | Acute Myeloid Leukemia | Completed | 2018-03-27 | 2021-08-25 | ClinicalTrials.gov |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck S… | Phase2 | Advanced Head and Neck Squamous Cell Carcinoma | Terminated | 2018-03-27 | 2020-12-16 | ClinicalTrials.gov |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Ad… | Phase1 | Melanoma | Completed | 2017-12-01 | 2022-09-13 | ClinicalTrials.gov |
| NCT03307746 | A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell… | Phase1 | B Cell Lymphoma | Completed | 2017-11-23 | 2024-08-21 | ClinicalTrials.gov |
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Gr… | Phase1 | Glioma | Terminated | 2017-04-03 | 2022-12-31 | ClinicalTrials.gov |
| NCT02839265 | FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small … | Phase2 | Non-small Cell Lung Cancer (NSCLC) | Completed | 2016-07-01 | 2024-11-22 | ClinicalTrials.gov |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal … | Phase1 | Renal Cell Carcinoma (RCC) | Terminated | 2016-06-01 | 2018-11-16 | ClinicalTrials.gov |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC … | Phase1 | Squamous Cell Carcinoma of the Lung | Terminated | 2016-04-10 | 2018-09-26 | ClinicalTrials.gov |
| NCT02642016 | A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patien… | Phase1 | Advanced Cancer | Completed | 2015-12-01 | 2019-06-04 | ClinicalTrials.gov |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase1 | Carcinoma, Renal Cell | Terminated | 2015-10-01 | 2017-05-22 | ClinicalTrials.gov |
| NCT02473731 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck… | Phase1 | Squamous Cell Carcinoma of the Head and Neck | Completed | 2015-10-01 | 2016-10-10 | ClinicalTrials.gov |
| NCT02456701 | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the C… | Phase1 | Thyroid Cancer | Completed | 2015-06-01 | 2016-10-13 | ClinicalTrials.gov |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Cle… | Phase1 | Carcinoma, Renal Cell | Terminated | 2015-05-01 | 2017-11-03 | ClinicalTrials.gov |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With … | Phase1 | Unresectable Stage III or Stage IV Melanoma | Terminated | 2015-04-01 | 2016-11-09 | ClinicalTrials.gov |
| NCT02284971 | Pilot Study of SBRT and CDX-1127 in Prostate Cancer | Phase1 | Prostatic Neoplasms | Terminated | 2014-11-01 | 2016-04-07 | ClinicalTrials.gov |
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunoth… | Phase2 | Melanoma | Terminated | 2014-11-01 | 2018-10-03 | ClinicalTrials.gov |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem … | Phase2 | For Donors | Terminated | 2014-07-01 | 2016-04-13 | ClinicalTrials.gov |
| NCT01976585 | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and P… | Phase1 | Low-Grade B-cell Lymphoma | Completed | 2014-01-03 | 2020-11-20 | ClinicalTrials.gov |
| NCT02014909 | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult… | Phase1 | Advanced Cancer | Completed | 2014-01-01 | 2017-06-05 | ClinicalTrials.gov |
| NCT01997333 | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Ove… | Phase2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | Completed | 2013-11-01 | 2018-08-07 | ClinicalTrials.gov |
| NCT01791686 | Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit D… | Phase1 | Dense Deposit Disease | Terminated | 2013-01-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glio… | Phase2 | Glioblastoma | Completed | 2011-12-01 | 2016-05-17 | ClinicalTrials.gov |
| NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Gliobla… | Phase3 | Glioblastoma | Completed | 2011-11-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01465139 | A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers | Phase1 | Healthy | Completed | 2011-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01460134 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or H… | Phase1 | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma | Completed | 2011-10-01 | 2017-10-16 | ClinicalTrials.gov |
| NCT01156753 | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Br… | Phase2 | Breast Cancer | Completed | 2010-07-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle… | Phase2 | Bladder Cancer | Terminated | 2010-04-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00948961 | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 | Phase1 | Advanced Malignancies | Completed | 2009-09-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT00458601 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multifor… | Phase2 | Malignant Glioma | Completed | 2007-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT00648102 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally … | Phase1 | Breast Cancer | Completed | 2006-01-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00709462 | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic,… | Phase1 | Breast Cancer | Completed | 2004-03-01 | 2010-06-01 | ClinicalTrials.gov |
Total clinical trials: 65
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Normal Saline | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06650761 |
| CDX-622 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06650761 |
| Normal Saline | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06650761 |
| CDX-622 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06650761 |
| Normal Saline | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06650761 |
| CDX-622 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06650761 |
| Normal saline | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT05031624 |
| CDX-0159 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT05031624 |
| Normal saline | Other | Phase PHASE1 | Prurigo Nodularis | COMPLETED | NCT04944862 |
| CDX-0159 | Other | Phase PHASE1 | Prurigo Nodularis | COMPLETED | NCT04944862 |
| CDX-301 | Other | Phase PHASE1 | HER2-negative Breast Cancer | RECRUITING | NCT05029999 |
| CDX-1140 | Other | Phase PHASE1 | HER2-negative Breast Cancer | RECRUITING | NCT05029999 |
| PLD Chemotherapy | Drug | Phase PHASE1 | HER2-negative Breast Cancer | RECRUITING | NCT05029999 |
| CDX-1135 | Other | Phase PHASE1 | Dense Deposit Disease | TERMINATED | NCT01791686 |
| Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC | Other | Phase PHASE1 | Unresectable Stage III or Stage IV Melanoma | TERMINATED | NCT02413827 |
| Combination of varlilumab and ipilimumab | Other | Phase PHASE1 | Unresectable Stage III or Stage IV Melanoma | TERMINATED | NCT02413827 |
| CDX-301 and plerixafor | Other | Phase PHASE2 | For Donors | TERMINATED | NCT02200380 |
| CDX-301 | Other | Phase PHASE2 | For Donors | TERMINATED | NCT02200380 |
| CDX-301 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01465139 |
| "Investigator's Choice" chemotherapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01156753 |
| CDX-011 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01156753 |
| KTN3379 | Other | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT02014909 |
| vemurafenib | Other | Phase PHASE1 | Thyroid Cancer | COMPLETED | NCT02456701 |
| KTN3379 | Other | Phase PHASE1 | Thyroid Cancer | COMPLETED | NCT02456701 |
| rindopepimut | Other | Preclinical | Recurrent GBM | NO_LONGER_AVAILABLE | NCT03068650 |
| KLH | Other | Phase PHASE3 | Glioblastoma | COMPLETED | NCT01480479 |
| Temozolomide | Other | Phase PHASE3 | Glioblastoma | COMPLETED | NCT01480479 |
| Rindopepimut (CDX-110) with GM-CSF | Other | Phase PHASE3 | Glioblastoma | COMPLETED | NCT01480479 |
| CDX-1127 | Other | Phase PHASE1 | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma | COMPLETED | NCT01460134 |
| Combination of Varlilumab and Atezolizumab | Other | Phase PHASE1 | Carcinoma, Renal Cell | TERMINATED | NCT02543645 |
| SBRT | Other | Phase PHASE1 | Prostatic Neoplasms | TERMINATED | NCT02284971 |
| CDX1127 | Other | Phase PHASE1 | Prostatic Neoplasms | TERMINATED | NCT02284971 |
| glembatumumab vedotin | Other | Preclinical | Metastatic gpNMB Expressing Triple Negative Breast Cancer | NO_LONGER_AVAILABLE | NCT03067935 |
| Combination of varlilumab and sunitinib | Other | Phase PHASE1 | Carcinoma, Renal Cell | TERMINATED | NCT02386111 |
| Capecitabine | Other | Phase PHASE2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | COMPLETED | NCT01997333 |
| CDX-011 | Other | Phase PHASE2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | COMPLETED | NCT01997333 |
| CDX-0158 (formerly known as KTN-0158) | Other | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT02642016 |
| Phase II: Glembatumumab Vedotin | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Lung | TERMINATED | NCT02713828 |
| Phase I: Glembatumumab Vedotin | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Lung | TERMINATED | NCT02713828 |
| KTN3379 | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT02473731 |
| glembatumumab vedotin and CDX-301 | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT02302339 |
| glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab) | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT02302339 |
| glembatumumab vedotin and varlilumab | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT02302339 |
| glembatumumab vedotin | Other | Phase PHASE2 | Melanoma | TERMINATED | NCT02302339 |
| Chemotherapy | Drug | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01094496 |
| CDX-1307 Vaccine Regimen | Other | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01094496 |
| KLH | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT01498328 |
| Rindopepimut (CDX-110) with GM-CSF | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT01498328 |
| Bevacizumab | Other | Phase PHASE2 | Glioblastoma | COMPLETED | NCT01498328 |
| CDX-3379 (ERBB3 antibody) | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03580382 |
| Trametinib daily Until PD | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03580382 |
| CDX-014 | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | TERMINATED | NCT02837991 |
| Normal saline | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04146129 |
| CDX-0159 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04146129 |
| Poly-ICLC | Other | Phase PHASE1 | Low-Grade B-cell Lymphoma | COMPLETED | NCT01976585 |
| rhuFlt3L/CDX-301 | Other | Phase PHASE1 | Low-Grade B-cell Lymphoma | COMPLETED | NCT01976585 |
| CDX-3379 and cetuximab | Other | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT03254927 |
| CDX-0159 | Other | Phase PHASE1 | Cold Urticaria | COMPLETED | NCT04548869 |
| CDX-527 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT04440943 |
| Normal Saline | Other | Phase PHASE1 | Chronic Spontaneous Urticaria | COMPLETED | NCT04538794 |
| CDX-0159 | Other | Phase PHASE1 | Chronic Spontaneous Urticaria | COMPLETED | NCT04538794 |
| Poly ICLC | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | UNKNOWN | NCT03789097 |
| Radiation | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | UNKNOWN | NCT03789097 |
| Flt3L | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | UNKNOWN | NCT03789097 |
| Pembrolizumab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | UNKNOWN | NCT03789097 |
| CDX-1127 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03617328 |
| polyICLC | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03617328 |
| Montanide ISA-51 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03617328 |
| 6MHP | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03617328 |
| SBRT | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT04491084 |
| anti-CD40 antibody (CDX-1140) | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT04491084 |
| FLT3 Ligand (CDX-301) | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT04491084 |
| Chemotherapy | Drug | Phase PHASE1 | Melanoma | COMPLETED | NCT03329950 |
| pembrolizumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03329950 |
| CDX-301 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03329950 |
| CDX-1140 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03329950 |
| CDX-1140 | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | TERMINATED | NCT05484011 |
| odetiglucan | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | TERMINATED | NCT05484011 |
| Varlilumab | Other | Phase PHASE1 | Glioma | TERMINATED | NCT02924038 |
| poly-ICLC | Other | Phase PHASE1 | Glioma | TERMINATED | NCT02924038 |
| IMA950 | Other | Phase PHASE1 | Glioma | TERMINATED | NCT02924038 |
| CDX-1140 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT04364230 |
| PolyICLC | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT04364230 |
| NeoAg-mBRAF | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT04364230 |
| 6MHP | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT04364230 |
| Research blood draw | Other | Phase PHASE2 | Pancreatic Cancer | TERMINATED | NCT04536077 |
| CDX-1140 | Other | Phase PHASE2 | Pancreatic Cancer | TERMINATED | NCT04536077 |
| CDX-301 | Other | Phase PHASE2 | Pancreatic Cancer | TERMINATED | NCT04536077 |
| Varlilumab | Other | Phase PHASE1 | B Cell Lymphoma | COMPLETED | NCT03307746 |
| Glembatumumab Vedotin | Other | Phase EARLY_PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03473691 |
| Matching Placebo | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT05368285 |
| barzolvolimab | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | COMPLETED | NCT05368285 |
| Unpulsed DCs | Other | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| Varlilumab | Other | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| Temozolomide | Other | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| Human CMV pp65-LAMP mRNA-pulsed autologous DCs | Other | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| CDX-585 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT05788484 |
| Poly ICLC | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT03358719 |
| Nivolumab | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT03358719 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT03358719 |
| Decitabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT03358719 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT03358719 |
| Matching Placebo | Other | Phase PHASE2 | Chronic Inducible Urticaria | COMPLETED | NCT05405660 |
| barzolvolimab | Other | Phase PHASE2 | Chronic Inducible Urticaria | COMPLETED | NCT05405660 |
| CDX-301 | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT03804944 |
| Pembrolizumab (200mg IV for 30 minutes | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT03804944 |
| Focal Radiation therapy | Drug | Phase PHASE2 | Breast Cancer | RECRUITING | NCT03804944 |
| Matching Placebo | Other | Phase PHASE2 | Prurigo Nodularis | ACTIVE_NOT_RECRUITING | NCT06366750 |
| barzolvolimab | Other | Phase PHASE2 | Prurigo Nodularis | ACTIVE_NOT_RECRUITING | NCT06366750 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Normal Saline | Other | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT06650761 |
| CDX-622 | Other | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT06650761 |
| Questionnaire Administration | Other | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| Pembrolizumab | Other | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| Bevacizumab | Other | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | Other | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| Matching placebo | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06455202 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06455202 |
| Matching placebo | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06445023 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06445023 |
| Pembrolizumab | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04930783 |
| Nivolumab | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04930783 |
| NEOVAX | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04930783 |
| CDX-301 | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04930783 |
| Matching Placebo | Other | Phase PHASE3 | Chronic Inducible Urticaria | RECRUITING | NCT07266402 |
| Barzolvolimab | Other | Phase PHASE3 | Chronic Inducible Urticaria | RECRUITING | NCT07266402 |
| Matching placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06727552 |
| Barzolvolimab | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06727552 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| CDX-622 | Other | Phase PHASE1 | Mild to Moderate Asthma | RECRUITING | NCT07330778 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Standard of Care | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| barzolvolimab | Other | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Matching Placebo | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| barzolvolimab | Other | Phase PHASE2 | Eosinophilic Esophagitis | COMPLETED | NCT05774184 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | Drug | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| CDX-1140 | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| TCR-transduced T cells | Other | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Standard of Care | OTHER | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| Barzolvolimab | DRUG | Phase PHASE3 | Chronic Inducible Urticaria | RECRUITING | NCT07266402 |
| CDX-622 | DRUG | Phase PHASE1 | Mild to Moderate Asthma | RECRUITING | NCT07330778 |
| Matching placebo | DRUG | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06727552 |
| CDX-585 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT05788484 |
| odetiglucan | BIOLOGICAL | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | TERMINATED | NCT05484011 |
| Matching Placebo | DRUG | Phase PHASE3 | Chronic Inducible Urticaria | RECRUITING | NCT07266402 |
| barzolvolimab | BIOLOGICAL | Phase PHASE3 | Chronic Spontaneous Urticaria | RECRUITING | NCT07256392 |
| TCR-transduced T cells | BIOLOGICAL | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| Quality-of-Life Assessment | OTHER | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | BIOLOGICAL | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| PLD Chemotherapy | DRUG | Phase PHASE1 | HER2-negative Breast Cancer | RECRUITING | NCT05029999 |
| NEOVAX | BIOLOGICAL | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04930783 |
| Normal Saline | DRUG | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT06650761 |
| Research blood draw | PROCEDURE | Phase PHASE2 | Pancreatic Cancer | TERMINATED | NCT04536077 |
| anti-CD40 antibody (CDX-1140) | BIOLOGICAL | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT04491084 |
| FLT3 Ligand (CDX-301) | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT04491084 |
| CDX-527 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT04440943 |
| PolyICLC | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT04364230 |
| NeoAg-mBRAF | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT04364230 |
| Normal saline | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT05031624 |
| CDX-0159 | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT05031624 |
| Pembrolizumab (200mg IV for 30 minutes | DRUG | Phase PHASE2 | Breast Cancer | RECRUITING | NCT03804944 |
| Focal Radiation therapy | RADIATION | Phase PHASE2 | Breast Cancer | RECRUITING | NCT03804944 |
| Radiation | RADIATION | Phase PHASE1 | Non-Hodgkin's Lymphoma | RECRUITING | NCT03789097 |
| Flt3L | DRUG | Phase PHASE1 | Non-Hodgkin's Lymphoma | RECRUITING | NCT03789097 |
| Pembrolizumab | DRUG | Phase PHASE1 | Malignant Epithelial Neoplasms | ACTIVE_NOT_RECRUITING | NCT05349890 |
| Unpulsed DCs | BIOLOGICAL | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| Td | BIOLOGICAL | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| Human CMV pp65-LAMP mRNA-pulsed autologous DCs | BIOLOGICAL | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| polyICLC | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT03617328 |
| Montanide ISA-51 | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT03617328 |
| 6MHP | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT04364230 |
| CDX-3379 (ERBB3 antibody) | DRUG | Phase PHASE1 | Melanoma | TERMINATED | NCT03580382 |
| Trametinib daily Until PD | DRUG | Phase PHASE1 | Melanoma | TERMINATED | NCT03580382 |
| Glembatumumab Vedotin | DRUG | Phase EARLY_PHASE1 | Triple Negative Breast Cancer | WITHDRAWN | NCT03473691 |
| Poly ICLC | DRUG | Phase PHASE1 | Non-Hodgkin's Lymphoma | RECRUITING | NCT03789097 |
| Nivolumab | DRUG | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04930783 |
| Laboratory Biomarker Analysis | OTHER | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT03358719 |
| Decitabine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT03358719 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401 | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT03358719 |
| pembrolizumab | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT03329950 |
| CDX-1140 | BIOLOGICAL | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | TERMINATED | NCT05484011 |
| CDX-3379 and cetuximab | DRUG | Phase PHASE2 | Advanced Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT03254927 |
| rindopepimut | BIOLOGICAL | Preclinical | Recurrent GBM | NO_LONGER_AVAILABLE | NCT03068650 |
| Varlilumab | BIOLOGICAL | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| IMA950 | BIOLOGICAL | Phase PHASE1 | Glioma | TERMINATED | NCT02924038 |
| Stereotactic Body Radiotherapy (SBRT) | RADIATION | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| FLT3 Ligand Therapy (CDX-301) | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02839265 |
| CDX-014 | DRUG | Phase PHASE1 | Renal Cell Carcinoma (RCC) | TERMINATED | NCT02837991 |
| Phase II: Glembatumumab Vedotin | DRUG | Phase PHASE1 | Squamous Cell Carcinoma of the Lung | TERMINATED | NCT02713828 |
| Phase I: Glembatumumab Vedotin | DRUG | Phase PHASE1 | Squamous Cell Carcinoma of the Lung | TERMINATED | NCT02713828 |
| CDX-0158 (formerly known as KTN-0158) | BIOLOGICAL | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT02642016 |
| Combination of Varlilumab and Atezolizumab | DRUG | Phase PHASE1 | Carcinoma, Renal Cell | TERMINATED | NCT02543645 |
| vemurafenib | DRUG | Phase PHASE1 | Thyroid Cancer | COMPLETED | NCT02456701 |
| Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC | DRUG | Phase PHASE1 | Unresectable Stage III or Stage IV Melanoma | TERMINATED | NCT02413827 |
| Combination of varlilumab and ipilimumab | DRUG | Phase PHASE1 | Unresectable Stage III or Stage IV Melanoma | TERMINATED | NCT02413827 |
| Combination of varlilumab and sunitinib | DRUG | Phase PHASE1 | Carcinoma, Renal Cell | TERMINATED | NCT02386111 |
| glembatumumab vedotin and CDX-301 | DRUG | Phase PHASE2 | Melanoma | TERMINATED | NCT02302339 |
| glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab) | DRUG | Phase PHASE2 | Melanoma | TERMINATED | NCT02302339 |
| glembatumumab vedotin and varlilumab | DRUG | Phase PHASE2 | Melanoma | TERMINATED | NCT02302339 |
| glembatumumab vedotin | DRUG | Preclinical | Metastatic gpNMB Expressing Triple Negative Breast Cancer | NO_LONGER_AVAILABLE | NCT03067935 |
| SBRT | RADIATION | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT04491084 |
| CDX1127 | BIOLOGICAL | Phase PHASE1 | Prostatic Neoplasms | TERMINATED | NCT02284971 |
| ONT-10, Varlilumab combination | BIOLOGICAL | Phase PHASE1 | Advanced Breast Carcinoma | COMPLETED | NCT02270372 |
| CDX-301 and plerixafor | DRUG | Phase PHASE2 | For Donors | TERMINATED | NCT02200380 |
| KTN3379 | BIOLOGICAL | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck | COMPLETED | NCT02473731 |
| Capecitabine | DRUG | Phase PHASE2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | COMPLETED | NCT01997333 |
| Poly-ICLC | DRUG | Phase PHASE1 | Low-Grade B-cell Lymphoma | COMPLETED | NCT01976585 |
| rhuFlt3L/CDX-301 | DRUG | Phase PHASE1 | Low-Grade B-cell Lymphoma | COMPLETED | NCT01976585 |
| CDX-1135 | DRUG | Phase PHASE1 | Dense Deposit Disease | TERMINATED | NCT01791686 |
| Bevacizumab | BIOLOGICAL | Phase PHASE2 | Ovarian Clear Cell Adenocarcinoma | RECRUITING | NCT05231122 |
| KLH | DRUG | Phase PHASE2 | Glioblastoma | COMPLETED | NCT01498328 |
| Rindopepimut (CDX-110) with GM-CSF | DRUG | Phase PHASE2 | Glioblastoma | COMPLETED | NCT01498328 |
| CDX-301 | DRUG | Phase PHASE1 | HER2-negative Breast Cancer | RECRUITING | NCT05029999 |
| CDX-1127 | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT03617328 |
| "Investigator's Choice" chemotherapy | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01156753 |
| CDX-011 | DRUG | Phase PHASE2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | COMPLETED | NCT01997333 |
| Chemotherapy | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT03329950 |
| CDX-1307 Vaccine Regimen | BIOLOGICAL | Phase PHASE2 | Bladder Cancer | TERMINATED | NCT01094496 |
| poly-ICLC | BIOLOGICAL | Phase PHASE1 | Glioma | TERMINATED | NCT02924038 |
| Resiquimod | BIOLOGICAL | Phase PHASE1 | Advanced Malignancies | COMPLETED | NCT00948961 |
| CDX-1401 | BIOLOGICAL | Phase PHASE1 | Advanced Malignancies | COMPLETED | NCT00948961 |
| CDX-1401 in combination with Resiquimod and/or Poly-ICLC | BIOLOGICAL | Phase PHASE1 | Advanced Malignancies | COMPLETED | NCT00948961 |
| CDX1307 | BIOLOGICAL | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00709462 |
| CDX-1307 | BIOLOGICAL | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00648102 |
| Temozolomide | DRUG | Phase PHASE2 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03688178 |
| CDX-110 with GM-CSF | DRUG | Phase PHASE2 | Malignant Glioma | COMPLETED | NCT00458601 |
Total products: 329